2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
Saved in:
| Title: | 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. |
|---|---|
| Authors: | Leuzy, A.1 (AUTHOR) Antoine.Leuzy@med.lu.se, Ashton, N. J.2,3,4 (AUTHOR), Mattsson-Carlgren, N.1,5,6 (AUTHOR), Dodich, A.7,8 (AUTHOR), Boccardi, M.9,10 (AUTHOR), Corre, J.11 (AUTHOR), Drzezga, A.12 (AUTHOR), Nordberg, A.13,14 (AUTHOR), Ossenkoppele, R.1,15 (AUTHOR), Zetterberg, H.2,16,17,18 (AUTHOR), Blennow, K.2,16 (AUTHOR), Frisoni, G. B.9,19 (AUTHOR), Garibotto, V.7 (AUTHOR), Hansson, O.1,20 (AUTHOR) Oskar.Hansson@med.lu.se |
| Source: | European Journal of Nuclear Medicine & Molecular Imaging. Jul2021, Vol. 48 Issue 7, p2121-2139. 19p. 1 Chart. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 16197070 |
|---|---|
| DOI: | 10.1007/s00259-021-05258-7 |
